DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Manas Mishra Michael Erman"


3 mentions found


☆ Pfizer looks past COVID with $43 bln deal for cancer drug innovator Seagen
  + stars: | 2023-03-13 | by ( Manas Mishra Michael Erman | Manas Mishra | Michael Erman | ) www.reuters.com   time to read: +3 min
Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed for a targeted destructive effect and spare healthy cells. The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. The drugmaker expects more than $10 billion in sales from Seagen products in 2030, and another $15 billion from its other recent acquisitions. Pfizer said antitrust regulators could closely review the deal due to its size but eventually approve it. Pfizer rival Merck & Co Inc (MRK.N) and Seagen were in advanced deal talks last year but those reportedly collapsed over antitrust concerns.
☆ Paxlovid sales forecasts may change with Pfizer view on China
  + stars: | 2023-01-30 | by ( Manas Mishra Michael Erman | Manas Mishra | Michael Erman | ) www.reuters.com   time to read: +4 min
Analysts say they have based their 2023 Paxlovid sales estimates primarily on public details of announced deals, with a token amount of estimated China sales from before the country dropped the Zero-COVID policy. Their current estimates for over $10 billion in 2023 Paxlovid sales is less than half the $22 billion Pfizer is expected to report for 2022, according to Refinitiv data. Billions of dollars in Paxlovid sales could be at stake for Pfizer. Even without a deal to sell Paxlovid broadly in China, the company can still sell it there on the private market. China is "probably the only region that we're modeling a year-over-year increase in 2023" for Paxlovid, Conover said.
☆ Pfizer boosts 2022 COVID vaccine forecast, looks to pivot with deals, new drugs
  + stars: | 2022-11-01 | by ( Manas Mishra Michael Erman | Manas Mishra | Michael Erman | ) www.reuters.com   time to read: +3 min
Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion, and said new deals and drugs in development should help replace future declining vaccine sales and lost revenue from patent expirations. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns. Third-quarter sales of the COVID vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion. However, $7.51 billion in sales of Paxlovid, the company's COVID-19 antiviral treatment, fell short of estimates of $7.66 billion. Pfizer reported adjusted earnings of $1.78 per share in the third quarter, beating analysts' estimates by 39 cents.
0 next >>
Total: 3